William J. Sandborn

机构：University of San Diego · ORCID：0000-0002-3314-7960

发表论文 2100 篇 · 总被引 167077 次 · h-index 200

代表论文

• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 95)
• A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice (2024 · Nature Reviews Gastroenterology & Hepatology · 被引 79)
• Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) (2024 · Gastroenterology · 被引 66)
• A living organoid biobank of patients with Crohn’s disease reveals molecular subtypes for personalized therapeutics (2024 · Cell Reports Medicine · 被引 23)
• Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 14)
• Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies (2025 · Inflammatory Bowel Diseases · 被引 9)